  For many rare diseases with no approved preventive interventions, promising
interventions exist, yet it has been difficult to conduct a pivotal phase 3
trial that could provide direct evidence demonstrating a beneficial effect on
the target disease outcome. When a promising putative surrogate endpoint(s) for
the target outcome is available, surrogate-based provisional approval of an
intervention may be pursued. We apply the Causal Roadmap rubric to define a
surrogate endpoint based provisional approval causal roadmap, which combines
observational study data that estimates the relationship between the putative
surrogate and the target outcome, with a phase 3 surrogate endpoint study that
collects the same data but is very under-powered to assess the treatment effect
(TE) on the target outcome. The objective is conservative estimation/inference
for the TE with an estimated lower uncertainty bound that allows (through two
bias functions) for an imperfect surrogate and imperfect transport of the
conditional target outcome risk in the untreated between the observational and
phase 3 studies. Two estimators of TE (plug-in, nonparametric efficient
one-step) with corresponding inference procedures are developed. Finite-sample
performance of the plug-in estimator is evaluated in two simulation studies,
with R code provided. The roadmap is illustrated with contemporary Group B
Streptococcus vaccine development.
